{{Rsnum
|rsid=7586110
|Gene=UGT1A10
|Chromosome=2
|position=233681881
|Orientation=plus
|GMAF=0.292
|Gene_s=UGT1A7,UGT1A8,UGT1A9,UGT1A10
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(G;G)
|geno2=(G;T)
|geno3=(T;T)
}}{{ population diversity
| geno1=(G;G)
| geno2=(G;T)
| geno3=(T;T)
| CEU | 12.4 | 53.1 | 34.5
| HCB | 4.4 | 40.9 | 54.7
| JPT | 4.4 | 34.5 | 61.1
| YRI | 8.9 | 33.6 | 57.5
| ASW | 7.0 | 43.9 | 49.1
| CHB | 4.4 | 40.9 | 54.7
| CHD | 2.8 | 33.0 | 64.2
| GIH | 23.8 | 46.5 | 29.7
| LWK | 6.4 | 30.9 | 62.7
| MEX | 5.2 | 44.8 | 50.0
| MKK | 25.6 | 37.8 | 36.5
| TSI | 13.7 | 43.1 | 43.1
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs7586110
|Name_s=UGT1A7:-57T>G; UGT1A7:(-57)T>G; rs7586110
|Gene_s=UGT1A10, UGT1A6, UGT1A7, UGT1A8, UGT1A9
|Feature=Intron, Intron, Intron, Intron, Intron
|Evidence=PubMed ID:18349289
|Annotation=UGT1A7:-57T>G increases risk of anemia in irinotecan-treated patients.
|Drugs=irinotecan
|Drug Classes=
|Diseases=Anemia
|Curation Level=Curated
|PharmGKB Accession ID=PA162355490
}}

{{PharmGKB
|RSID=rs7586110
|Name_s=UGT1A7:-57T>G; UGT1A7:(-57)T>G; rs7586110
|Gene_s=UGT1A10, UGT1A6, UGT1A7, UGT1A8, UGT1A9
|Feature=Intron, Intron, Intron, Intron, Intron
|Evidence=PubMed ID:18349289
|Annotation=UGT1A7:-57T>G increases risk of anameia in irinotecan-treated patients.
|Drugs=irinotecan
|Drug Classes=
|Diseases=Anemia
|Curation Level=Curated
|PharmGKB Accession ID=PA162355486
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs7586110
|overall_frequency_n=43
|overall_frequency_d=122
|overall_frequency=0.352459
|n_genomes=28
|n_genomes_annotated=0
|n_haplomes=35
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | FTDNA}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}